It May Be Prilosec Time For AndrxBy
For a little-known pharmaceutical house, Andrx (ADRX) has attracted a lot of big-name investors, including Janus Capital, with an 8% stake; TCW Group, with 5%; and Fidelity Management, with 3.4%. "Andrx has exciting products that target huge markets," says Merrill Lynch analyst Gregory Gilbert. Andrx formulates controlled-release oral medicines, including generic versions of brand-name products such as Prilosec, the largest-selling drug, with sales topping $4 billion in 2000. Prilosec treats stomach ulcers and heartburn.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.